The link you have selected will take you to a site outside xeneticbio.com.

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

Xenetic Biosciences, Inc.

menu
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
  • Technology
    • DNase I Oncology Platform
    • Publications
  • Pipeline
    • Overview
    • XBIO-015
    • XBIO-020
  • News & Media
    • Press Releases
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Dec 17, 2024

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Dec 16, 2024

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Dec 5, 2024

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Nov 22, 2024

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Nov 21, 2024

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 13, 2024

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 12, 2024

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Nov 7, 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 22, 2024

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Oct 17, 2024
  • 1
  • 2
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2025Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap